PTC Therapeutics (PTCT) reported revenue at $190 million, provides guidance

PTC Therapeutics (NASDAQ: PTCT) reported revenue for the quarter came in at $190 million versus the consensus estimate of $167.54 million.

GUIDANCE:

PTC Therapeutics sees FY2025 revenue of $650-800 million, versus the consensus of $829.9 million.

PTC anticipates full-year 2025 GAAP R&D and SG&A expense to be between $805 and $835 million.
PTC anticipates full-year 2025 non-GAAP R&D and SG&A expense to be between $730 and $760 million, excluding estimated non-cash, stock-based compensation expense of $75 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c